GSK's albiglutide fails to match Victoza in its first Phase III trial
This article was originally published in Scrip
A head-to-head Phase III study of GlaxoSmithKline's once-weekly experimental GLP-1 agonist albiglutide (Syncria) failed to show non-inferiority to Novo Nordisk's Victoza (liraglutide) in patients with type 2 diabetes.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.